

Mieke Van Bockstal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9335455/publications.pdf>

Version: 2024-02-01

84
papers

1,326
citations

430874

18
h-index

377865

34
g-index

86
all docs

86
docs citations

86
times ranked

2608
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to Kawasaki et al Regarding "Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast" International Journal of Surgical Pathology, 2022, , 106689692110701.	0.8	0
2	Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast. Journal of Mammary Gland Biology and Neoplasia, 2022, 26, 367.	2.7	1
3	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). Cancer Research, 2022, 82, P1-02-09-P1-02-09.	0.9	0
4	Abstract P2-14-12: B-immune interim analysis: A phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers. Cancer Research, 2022, 82, P2-14-12-P2-14-12.	0.9	0
5	The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology, 2022, 89, 393-406.	3.8	5
6	Interobserver agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	3.0	19
7	Isolated CEP17 Copy Number Gain in Invasive Breast Cancer Results in a "Reverse" Amplification Status. International Journal of Surgical Pathology, 2021, 29, 76-77.	0.8	0
8	Multinucleated Stromal Giant Cells in a Benign Fibroadenoma: Do Not Make a Mountain Out of a Molehill!. International Journal of Surgical Pathology, 2021, 29, 182-183.	0.8	0
9	Periductal Stromal Tumors and Phyllodes Tumors Represent a Spectrum of Fibroepithelial Lesions: What Is in a Name?. International Journal of Surgical Pathology, 2021, 29, 97-101.	0.8	3
10	The Impact of the COVID-19 Pandemic and the Associated Belgian Governmental Measures on Cancer Screening, Surgical Pathology and Cytopathology. Pathobiology, 2021, 88, 46-55.	3.8	55
11	The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?. Pathobiology, 2021, 88, 88-94.	3.8	28
12	Comment on: "Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project" British Journal of Cancer, 2021, 124, 1461-1462.	6.4	2
13	Artefactual Epithelial Displacement in a Papilloma with Extensive Usual Duct Hyperplasia Mimics a Solid Papillary Carcinoma with Invasive Growth. International Journal of Surgical Pathology, 2021, 29, 395-399.	0.8	0
14	Not All Cases of Mammary Paget's Disease are Cytokeratin-7 Positive: A Challenging Diagnosis!. International Journal of Surgical Pathology, 2021, 29, 631-634.	0.8	1
15	Histological interpretation of differentiated vulvar intraepithelial neoplasia (dVIN) remains challenging" observations from a bi-national ring-study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 305-315.	2.8	13
16	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
17	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910.	3.7	8
18	The 5-Year Paradigm in DCIS of the Breast: Unexpected Lessons From the NSABP B-43 Trial. Journal of Clinical Oncology, 2021, 39, JCO.21.00968.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast. <i>International Journal of Surgical Pathology</i> , 2021, 29, 106689692098593.	0.8	8
20	Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 33-43.	2.8	1
21	A retrospective alternative for active surveillance trials for ductal carcinoma <i>in situ</i> of the breast. <i>International Journal of Cancer</i> , 2020, 146, 1189-1197.	5.1	16
22	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020, 33, 354-366.	5.5	25
23	Granular dot-like staining with MLH1 immunohistochemistry is a clone-dependent artefact. <i>Pathology Research and Practice</i> , 2020, 216, 152581.	2.3	7
24	Ductal carcinoma in situ of the breast: immune cell composition according to subtype. <i>Modern Pathology</i> , 2020, 33, 196-205.	5.5	15
25	25P Breast cancers with heterogeneous HER2 amplification show a diverse distribution of "driver" and "passenger" somatic mutations and copy number variations. <i>Annals of Oncology</i> , 2020, 31, S25.	1.2	0
26	Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 335-343.	1.4	10
27	38P Morphological heterogeneity in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2020, 31, S28-S29.	1.2	0
28	Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151634.	1.3	13
29	Stemness in high-grade serous carcinoma of tubo-ovarian origin causes multiple immunohistochemical pitfalls: a case report. <i>Journal of Clinical Pathology</i> , 2020, 73, 845-846.	2.0	0
30	Interobserver Variability in Ductal Carcinoma In Situ of the Breast. <i>American Journal of Clinical Pathology</i> , 2020, 154, 596-609.	0.7	17
31	18F-FDG micro-PET/CT for intra-operative margin assessment during breast-conserving surgery. <i>Acta Chirurgica Belgica</i> , 2020, 120, 366-374.	0.4	11
32	Somatic mutations and copy number variations in breast cancers with heterogeneous <i>HER2</i> amplification. <i>Molecular Oncology</i> , 2020, 14, 671-685.	4.6	27
33	Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment. <i>International Journal of Cancer</i> , 2020, 147, 554-564.	5.1	14
34	Adenoid cystic carcinoma of the Bartholin gland is not HPV-related: A case report and review of literature. <i>Pathology Research and Practice</i> , 2020, 216, 152968.	2.3	6
35	Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent. <i>Modern Pathology</i> , 2020, 33, 1773-1782.	5.5	8
36	Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
37	Deciduososis of the appendix: a rare cause of acute abdomen during pregnancy: a case report. Pan African Medical Journal, 2020, 37, 316.	0.8	1
38	Histiocytoid Ductal Carcinoma In Situ of the Breast: Not All Intraductal Foamy Cells Are Macrophages!. International Journal of Surgical Pathology, 2019, 27, 872-875.	0.8	0
39	Splenic metabolic activity as biomarker in cervical cancer. Annals of Oncology, 2019, 30, v47-v48.	1.2	1
40	miRNA expression profiles in BRCA1-associated breast cancers reveal upregulation of specific miRNAs in tumors lacking a clear second hit in a large proportion of the tumour. Annals of Oncology, 2019, 30, iii72.	1.2	0
41	Ductal carcinoma in situ of the breast: Immune cell composition according to subtype. Annals of Oncology, 2019, 30, iii5.	1.2	2
42	The Sick Breast Lobe Has a Testicular Counterpart. International Journal of Surgical Pathology, 2019, 27, 876-877.	0.8	0
43	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology, 2019, 45, 550-559.	1.0	14
44	The role of routine histopathology after chest-contouring surgery in transmen. European Journal of Surgical Oncology, 2019, 45, 485-486.	1.0	1
45	<sc>HER</sc>2 protein overexpression in non–amplified ductal carcinoma <i>in–situ</i>: quality issue or transcription mechanisms gone awry?. Histopathology, 2019, 74, 666-668.	2.9	1
46	Abstract P3-13-04: 18F-FDG micro-PET/CT for intraoperative margin assessment in breast conserving surgery using: A proof-of-concept study. , 2019, , .		0
47	Abstract 2704: Ductal carcinoma in situ of the breast: Immune cell subset composition according to subtype. , 2019, , .		0
48	P1235–. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment. , 2019, , .		0
49	Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in schwannomas: the chosen clone matters. Human Pathology, 2018, 76, 167-168.	2.0	1
50	Routine histopathological examination after female-to-male gender-confirming mastectomy. British Journal of Surgery, 2018, 105, 885-892.	0.3	24
51	Some diffuse large B cell lymphomas (<sc>DLBCL</sc>s) present with clone–dependent <sc>TTF</sc>–positivity. Histopathology, 2018, 72, 1228-1230.	2.9	3
52	Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits. Cancer Letters, 2018, 425, 125-133.	7.2	12
53	A Rare Mammary Serendipity: Mucinous Metaplasia of the Breast. International Journal of Surgical Pathology, 2018, 26, 730-730.	0.8	0
54	A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer. Breast, 2018, 37, 52-55.	2.2	10

#	ARTICLE	IF	CITATIONS
55	Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. <i>BMC Cancer</i> , 2018, 18, 1101.	2.6	16
56	EXclusion of non-Involved uterus from the Target Volume (EXIT-trial): an individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques. <i>BMC Cancer</i> , 2018, 18, 898.	2.6	2
57	Dichotomous histopathological assessment of ductal carcinoma <i>in situ</i> of the breast results in substantial interobserver concordance. <i>Histopathology</i> , 2018, 73, 923-932.	2.9	21
58	Collagen Alignment and Recurrence of DCIS Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 613-613.	2.5	0
59	Whipple's disease in granulomatous disguise: a challenging diagnosis with many histopathological pitfalls. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 465-468.	2.8	8
60	Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 575-587.	2.8	12
61	A JAK3/STAT3 passenger activation in a lapatinib-acquired resistance model of HER2-amplified breast cancer. <i>Breast</i> , 2017, 32, S48.	2.2	0
62	Inter-rater reliability in the assessment of stromal characteristics in ductal carcinoma <i>in situ</i> of the breast: how consistent are we?. <i>Breast</i> , 2017, 32, S48-S49.	2.2	0
63	Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA. <i>Journal of Controlled Release</i> , 2017, 266, 287-300.	9.9	98
64	Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma <i>in situ</i> of the breast: another causality dilemma?. <i>Annals of Oncology</i> , 2017, 28, 2317.	1.2	5
65	Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth. <i>Oncotarget</i> , 2017, 8, 47239-47249.	1.8	13
66	Abstract P1-03-14: Assessment of stromal characteristics in ductal carcinoma <i>in situ</i> of the breast: An inter-observer variability study. , 2017, , .		0
67	The Baader-Meinhof phenomenon in ductal carcinoma <i>in situ</i> of the breast. <i>Histopathology</i> , 2016, 69, 522-523.	2.9	5
68	Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: <i>In vitro</i> and <i>in vivo</i> characterization. <i>Biomaterials</i> , 2016, 96, 33-46.	11.4	117
69	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4746-4755.	7.0	59
70	Fibroblast-induced matrix remodeling paves the path for invasion. <i>Cell Cycle</i> , 2015, 14, 793-794.	2.6	1
71	Hemangiomas of the spleen in a patient with Klippel-Tränaunay syndrome. <i>Journal of the Belgian Society of Radiology</i> , 2015, 96, 357.	0.2	2
72	2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 1856-1857.	1.6	17

#	ARTICLE	IF	CITATIONS
73	Cancer-Associated Adipose Tissue Promotes Breast Cancer Progression by Paracrine Oncostatin M and Jak/STAT3 Signaling. <i>Cancer Research</i> , 2014, 74, 6806-6819.	0.9	105
74	Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 275-289.	2.8	33
75	Carcinoma-associated fibroblasts provide operational flexibility in metastasis. <i>Seminars in Cancer Biology</i> , 2014, 25, 33-46.	9.6	111
76	Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF- β 1 regulates cancer cell spreading but not adhesion. <i>Oncoscience</i> , 2014, 1, 634-648.	2.2	40
77	Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. <i>Proteomics</i> , 2013, 13, 379-388.	2.2	85
78	Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 140, 561-566.	0.7	60
79	Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma <i>in situ</i> of the breast. <i>Histopathology</i> , 2013, 63, 520-533.	2.9	30
80	Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model. <i>Cancer Letters</i> , 2012, 326, 69-78.	7.2	44
81	Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 393-398.	2.5	23
82	Glypican-3 is a marker for solid pseudopapillary neoplasm of the pancreas. <i>Histopathology</i> , 2011, 59, 1278-1279.	2.9	7
83	Malignant Peritoneal Mesothelioma in a Patient With Li-Fraumeni Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e503-e505.	1.6	11
84	P4-18-06: Relationship between Pathological Features, Her2 Protein Expression, and HER2 and CEP17 Copy Numbers in DCIS., 2011, , .		0